welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Colon-Specific Delivery of Celecoxib is a Potential Strategy to Improve Toxicological and Pharmacological Properties...In general, colon-specific delivery of a...
-
Evaluation of 28 Years of Surgical Treatment of Children and Young Adults with Familial Adenomatous PolyposisBACKGROUND : In this retrospective study...
-
Surgical Prophylaxis in Familial Adenomatous Polyposis: Do Pre-Existing Desmoids Outside the Abdominal Cavity Matter...Desmoid tumours (DT) are myofibroblastic...
-
Long-Term Treatment with Sulindac in Familial Adenomatous Polyposis: A Prospective Cohort StudyBACKGROUND & AIMS : Management of pa...
-
Therapeutic Approaches for Patients with Coexisting Familial Adenomatous Polyposis and Colorectal CancerColorectal cancer is a major cause of de...
-
Curcumin in Treating Patients With Familial Adenomatous PolyposisThis clinical trial studies curcumin in ...